iPS cells Japan

Parkinson’s IPS cell trial in Japan switching to allogeneic

Jun-Takahashi

What’s better for stem cell trials such as for vision loss or Parkinson’s Disease: allogeneic or autologous cells? In a major shift earlier this year, the induced pluripotent stem (IPS) cell trial in Japan for treatment of macular degeneration (MD) switched gears from using the patients’ own cells (called “autologous”) to using banked cells from …

Parkinson’s IPS cell trial in Japan switching to allogeneic Read More »

FDA & Japanese Health Ministry (厚生労働省) To Develop Joint iPS cell clinical rules by 2015 while first human studies to begin earlier in 2014

In a rare sign of stem cell international regulatory unity, the Japanese Health Ministry (厚生労働省) and the US FDA have agreed to develop a joint, unified regulatory framework for clinical studies of human iPS cells for use in treating retinal diseases. Presumably the rules would also guide clinical use of iPS cells to treat other …

FDA & Japanese Health Ministry (厚生労働省) To Develop Joint iPS cell clinical rules by 2015 while first human studies to begin earlier in 2014 Read More »